Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (SAM) are the ideal recommendations for prostate cancer prevention

被引:3
作者
Moyad, Mark A. [1 ]
Vogelzang, Nicholas J. [2 ,3 ]
机构
[1] Univ Michigan, Med Ctr, Dept Urol, Ann Arbor, MI 48109 USA
[2] Comprehens Canc Ctr Nevada, Dev Therapeut Comm, Las Vegas, NV USA
[3] Comprehens Canc Ctr Nevada, US Oncol Res, Genitourinary Comm, Las Vegas, NV USA
关键词
aspirin; diet; lifestyle; metformin; prostate cancer; statins; LIFE-STYLE INTERVENTION; TYPE-2; DIABETES-MELLITUS; CARDIOVASCULAR-DISEASE; VITAMIN-E; SELENIUM SUPPLEMENTATION; PHYSICIANS HEALTH; ALL-CAUSE; MEDITERRANEAN DIET; INSULIN-RESISTANCE; 5-ALPHA-REDUCTASE INHIBITORS;
D O I
10.4103/1008-682X.148070
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Cardiovascular disease (CVD) has been the number one cause of death in the U.S. for 114 of the last 115 years. Lifestyle factors that promote CVD also appear to increase prostate cancer risk and those that reduce CVD risk also appear to reduce the risk of prostate cancer. The largest randomized trials utilizing dietary supplements or pharmacologic agents for prostate cancer prevention (Selenium and Vitamin E Cancer Prevention Trial [SELECT]) have also shed light on the problems and future solutions in this area. Dietary supplements that have not been found to be CVD protective, such as selenium and Vitamin E have not been found to be prostate protective. In addition, over exposure to specific anti-oxidants in nutritionally replete populations may be encouraging cancer growth. Future trials of dietary supplements to prevent prostate cancer could be problematic because by the time a definitive trial is initiated the participants will no longer be "deficient" in the nutrient being tested, which arguably occurred in the SELECT trial. It is also interesting that statins, aspirin, and/or metformin (S.A.M.) are 3 generic, low-cost, heart healthy agents derived from natural sources with separate mechanism of actions, which all appear to have the best benefit to risk ratio compared to any other agent available for prostate cancer prevention, especially aggressive disease, or as an ancillary agent (s) to conventional cancer treatment. It is time to focus on the forest over the trees and recommend proven CVD protective measures for men concerned about their risk of prostate cancer.
引用
收藏
页码:783 / 791
页数:9
相关论文
共 151 条
  • [1] Agaku Israel, 2012, Morbidity and Mortality Weekly Report, V61, P889
  • [2] Serum Insulin, Glucose, Indices of Insulin Resistance, and Risk of Prostate Cancer
    Albanes, Demetrius
    Weinstein, Stephanie J.
    Wright, Margaret E.
    Mannisto, Satu
    Limburg, Paul J.
    Snyder, Kirk
    Virtamo, Jarmo
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (18): : 1272 - 1279
  • [3] Effect of Dutasteride on the Risk of Prostate Cancer.
    Andriole, Gerald L.
    Bostwick, David G.
    Brawley, Otis W.
    Gomella, Leonard G.
    Marberger, Michael
    Montorsi, Francesco
    Pettaway, Curtis A.
    Tammela, Teuvo L.
    Teloken, Claudio
    Tindall, Donald J.
    Somerville, Matthew C.
    Wilson, Timothy H.
    Fowler, Ivy L.
    Rittmaster, Roger S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (13) : 1192 - 1202
  • [4] Mortality Results from a Randomized Prostate-Cancer Screening Trial
    Andriole, Gerald L.
    Grubb, Robert L., III
    Buys, Saundra S.
    Chia, David
    Church, Timothy R.
    Fouad, Mona N.
    Gelmann, Edward P.
    Kvale, Paul A.
    Reding, Douglas J.
    Weissfeld, Joel L.
    Yokochi, Lance A.
    Crawford, E. David
    O'Brien, Barbara
    Clapp, Jonathan D.
    Rathmell, Joshua M.
    Riley, Thomas L.
    Hayes, Richard B.
    Kramer, Barnett S.
    Izmirlian, Grant
    Miller, Anthony B.
    Pinsky, Paul F.
    Prorok, Philip C.
    Gohagan, John K.
    Berg, Christine D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) : 1310 - 1319
  • [5] The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
    Anfossi, Giovanni
    Russo, Isabella
    Bonomo, Katia
    Trovati, Mariella
    [J]. CURRENT VASCULAR PHARMACOLOGY, 2010, 8 (03) : 327 - 337
  • [6] [Anonymous], TOB SMOK CAUS DIS BI
  • [7] [Anonymous], HLTH BEN SMOK CESS R
  • [8] [Anonymous], PROMOTING WELLNESS P
  • [9] [Anonymous], COMPLEMENTARY ALTERN
  • [10] The effects of a smoking cessation intervention on 14.5-year mortality - A randomized clinical trial
    Anthonisen, NR
    Skeans, MA
    Wise, RA
    Manfreda, J
    Kanner, RE
    Connett, JE
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 142 (04) : 233 - 239